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Abstract
Background: The impact of highly active antiretroviral therapy (HAART) on health-related quality
of life (QOL) of HIV-1 infected individuals in large prospective cohorts has not been well studied.
Objective: To assess the effect of HAART on QOL by comparing HIV-infected women using
HAART with HIV-infected women remaining HAART naïve in the Women's Interagency HIV Study
(WIHS), a multicenter prospective cohort study begun in 1994 in the US.
Methods: A 1:1 matching with equivalent (≤ 0.1%) propensity scores for predicting HAART
initiation was implemented and 458 pairs were obtained. HAART effects were assessed using
pattern mixture models. The changes of nine QOL domain scores and one summary score derived
from a shortened version of the MOS-HIV from initial values were used as study outcomes.
Results: The background covariates of the treatment groups were well-balanced after propensity
score matching. The 916 matched subjects had a mean age of 38.5 years and 42% had a history of
AIDS diagnosis. The participants contributed a total of 4,292 person visits with a median follow-up
time of 4 years. In the bivariate analyses with only HAART use and time as covariates, HAART was
associated with short-term improvements of 4 QOL domains: role functioning, social functioning,
pain and perceived health index. After adjusting for demographic, socioeconomic, biological and
clinical variables, HAART had small but significant short-term improvements on changes in
summary QOL (mean change: 3.25; P = 0.02), role functioning (6.99; P < 0.01), social functioning
(5.74; P < 0.01), cognitive functioning (3.59; P = 0.03), pain (6.73; P < 0.01), health perception (3.67;
P = 0.03) and perceived health index (4.87; P < 0.01). These QOL scores typically remained stable
or declined over additional follow-up and there was no indication that HAART modified these
trends.
Conclusion:  Our study demonstrated significant short-term HAART effects on most QOL
domains, but additional use of HAART did not modify long-term trends. These changes could be
attributed to the direct effect of HAART and indirect HAART effect mediated through clinical
changes.
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Background
As an important measure of self-reported health and well-
being, health-related quality of life (QOL) has been
widely applied in evaluating treatment effects among dif-
ferent populations[1]. The effectiveness of highly active
antiretroviral therapy (HAART) in arresting viral replica-
tion and reducing HIV-related morbidity and mortality
has been consistently demonstrated [2-4]; however, its
impact on QOL has been unclear.
Published study findings have varied between reporting
positive[5,6] or negative effects of HAART on QOL[7,8],
with documented improvements often of minimal or
modest change [9-12]. A number of these studies have
been nested in clinical trials which are typically of short
duration and enroll selected study populations[13,14]
resulting in under-representation of women, minorities,
and substance users who now comprise an increasingly
important demographic component of the HIV epi-
demic[14,15], Observational studies offer an opportunity
to examine long-term changes in more heterogeneous
populations. However, without randomized treatment
assignments, these studies may be influenced by unbal-
anced distributions of disease stage and background cov-
ariates that complicate unconfounded comparisons of
treatment groups[16]. Although HAART has been availa-
ble since the introduction of protease inhibitors in 1996,
its long-term effect on QOL has rarely been assessed in
large prospective cohort studies[17].
The primary objective of this study was to assess the effect
of HAART on QOL change by comparing HIV-infected
women using HAART with women remaining HAART
naïve. To evaluate this question, we utilized data from the
Women's Interagency HIV Study (WIHS), one of the larg-
est prospective cohort studies of HIV-infected and at-risk
women in the U.S. Acknowledging the challenges encoun-
tered in the analysis of observational data, we utilized
methods that balanced the distributions of many back-
ground covariates through matching based upon a pro-
pensity score, the estimated probability of HAART
initiation, and effectively handled informative drop-out
by using a pattern mixture model.
Methods
Study population
The WIHS is a multicenter prospective study designed to
explore the natural and treated history of HIV disease
among women since 1994. The WIHS study design and
methods are detailed elsewhere[18]. Briefly, a total of
3,768 HIV-seropositive or high risk HIV-negative women
aged 13 years or older were recruited from six consortia
sites located in Chicago, Los Angeles, San Francisco,
Washington D.C., Brooklyn and Bronx in New York City.
The study was approved by the local institutional review
board at each site and informed consent was obtained for
all participants. Research visits are conducted semiannu-
ally and include extensive questionnaire-based interviews,
specimen collection, physical and obstetric/gynecologic
examination. Self-reported quality of life was ascertained
at each semiannual visit through 1999 and annually
thereafter. This analysis uses data collected through Sep-
tember 2004 (study visit 20). For this study, a matched
cohort design was adopted and our analyses were
restricted to the HIV-positive participants who enrolled in
WIHS during 1994–1995 and had at least one QOL meas-
urement after the matching (baseline) visit as described in
detail below.
Study variables
Among many QOL instruments used for HIV-infected
populations, the Medical Outcome Study (MOS)-HIV has
been one of the most widely used disease specific instru-
ments. In WIHS, a shortened version of MOS-HIV devel-
oped by Bozzette et al[19] was adopted to measure QOL.
With this instrument, item redundancy is reduced while
excellent reliability is maintained and construct validity is
comparable to that of MOS-HIV. The shortened form has
21 items representing 9 domains: physical functioning,
role functioning, energy/fatigue, social functioning, cog-
nitive functioning, pain, emotional well-being, perceived
health index and current health perception. The domain
scores are derived by averaging the recoded raw scores for
corresponding items of each domain expressed on a 0–
100 scale, with higher values for better functioning and
well-being according to an established scoring recom-
mendation. In addition, one summary score is generated
from six domains (physical functioning, role functioning,
energy/fatigue, social functioning, pain and emotional
well-being) on the basis of a published algorithm[19].
The summary and nine domain scores are the outcomes of
interest in this study.
HAART was defined following the Department of Health
and Human Service/Kaiser Panel guidelines[20] and
defined as: (a) two or more nucleoside reverse tran-
scriptase inhibitors (NRTIs) in combination with at least
one protease inhibitor (PI) or one non-nucleoside reverse
transcriptase inhibitor (NNRTI); (b) one NRTI in combi-
nation with at least one PI and at least one NNRTI; and (c)
an abacavir or tenofovir containing regimen of three or
more NRTIs in the absence of both PIs and NNRTIs. Com-
binations of zidovudine (AZT) and stavudine (d4T) with
either a PI or NNRTI were not considered HAART. While
HAART use can vary over time, in this analysis we consider
trends following first HAART initiation.
On the basis of results from prior studies and data availa-
ble in WIHS, we selected a number of variables possibly
affecting participants' and/or provider's decision to initi-AIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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ate HAART or their QOL. Age was determined at the
matching visit. Race/ethnicity was categorized as White
non-Hispanic, Black non-Hispanic, Latina/Hispanic and
other. Education level at study entry was coded as less
than high school, completed high school, and above high
school. Annual gross income was dichotomized as greater
than $12,000 or not. The number of HIV-related constitu-
tional symptoms, including fever, diarrhea, memory
problems, neuropathy symptoms (numbness, tingling or
burning), unintentional weight loss, confusion and night
sweats, were aggregated for each visit. Standardized three
or four color flow cytometry was used to determine total
CD4+ cells/mm3 at laboratories concurrently[21] at each
visit. Plasma HIV-1 RNA levels were measured using the
isothermal nucleic acid sequence based amplification
(NASBA/Nuclisens) method (bioMérieux, Boxtel, NL) in
laboratories participating in the NIH/NIAID Virology
Quality Assurance Laboratory proficiency testing pro-
gram. The current lower limit of quantification was 80
copies/ml using 1.0 ml sample input. Self-reported
depressive symptoms was measured using the 20-item
Center for Epidemiological Studies Depression Scale
(CES-D)[22], with a total score of 16 or greater used to
define the presence of depression. Current employment,
any insurance coverage, clinical AIDS diagnosis, and the
number of outpatient visits, hospitalizations and medica-
tions taken (antiretroviral and non-antiretroviral) since
last visit, were also included in our analysis. As calendar
time affected the chance of HAART initiation[3,16], it was
also included as a covariate in estimating propensity
score.
Statistical analysis
Propensity score matching
Unlike in randomized trials, use of therapies in observa-
tional studies is not from random assignment and thus
Table 1: Study Participant Characteristics Before and After Propensity Score Matching. Numbers indicate mean value unless 
otherwise noted.
Before Matching After Matching
Covariates HAART Naive 
(N = 555)
HAART Users 
(N = 1271)
P-Value HAART Naive 
(N = 458)
HAART Users 
(N = 458)
P-Value
Age at baseline 38.6 38.4 0.42 38.6 38.4 0.75
Education % <.01 0.30
Less than high school 39.8 35.5 40.8 39.1
Completed high school 33.2 31.2 31.7 29.5
College and above 27.0 33.4 27.5 31.4
Race % 0.02 0.35
White non-Hispanic 15.1 18.5 16.4 17.5
Black non-Hispanic 62.5 53.8 60.7 56.6
Hispanic 3.9 3.5 4.1 3.1
Others 18.5 24.2 18.8 22.9
Annual gross income (>$12,000) % 35.0 38.9 0.02 36.9 37.6 0.84
Employment % 26.6 25.3 0.37 21.6 25.5 0.16
Insurance % 40.2 23.4 <.01 26.6 30.8 0.17
CD4+ cell count 533.8 301.9 <.01 339.4 344.9 0.74
Viral Load (log10) 3.7 4.0 <.01 4.2 4.1 0.17
AIDS diagnosis % 36.4 44.3 <.01 43.2 41.9 0.69
Depression % 50.0 47.4 0.11 49.8 49.8 1.00
Number of symptoms 1.3 1.5 0.03 1.5 1.5 0.84
Number of outpatient visit 3.8 5.9 <.01 5.1 4.9 0.71
Number of hospitalizations 0.3 0.3 0.16 0.4 0.3 0.43
Number of medications 2.8 3.8 <.01 3.7 3.4 0.13
Quality of life scores
Physical functioning 66.2 64.1 0.03 63.1 65.5 0.23
Role functioning 74.0 73.0 0.28 74.0 74.1 0.98
Energy/Fatigue 54.1 53.0 0.20 51.6 53.1 0.39
Social functioning 72.0 72.0 0.92 73.0 72.2 0.65
Cognitive functioning 76.7 78.1 0.09 78.6 77.1 0.33
Pain 69.9 69.5 0.64 70.2 69.1 0.55
Emotion well-being 59.8 59.9 0.95 59.1 59.0 0.94
Perceived health index 53.7 51.6 0.01 50.8 52.2 0.40
Health rating 66.4 68.1 0.02 66.9 67.1 0.89
Summary score 63.2 62.3 0.19 61.9 62.5 0.65AIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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unbalanced distributions of background confounders
may bias the estimated exposure effects. To account for
this, conventional matching or stratification methods can
sometimes be used to create groups of exposed and unex-
posed individuals with similar measured covariates.
Given the large number of background covariates and
limited sample size in most observational studies, it is
often implausible to control all covariates at one time in
this way. As an alternative, propensity score methods have
been developed[23] that attempt to match or stratify on a
scalar propensity score that reflects an individual's esti-
mated probability of taking a treatment conditional on
other variables. By selecting exposed and unexposed indi-
viduals matched on the propensity score, we eliminate the
associations between HAART initiation and these covari-
ates; thus, these factors will not serve as confounders
when we evaluate the effect of HAART. As many factors
could affect HAART initiation in WIHS, it is reasonable to
use propensity score matching to help eliminate indica-
tion bias.
To construct the propensity score of initiating HAART in
our analysis, a multiple logistic regression method was
used. For the HAART users, we selected the last visit before
HAART initiation as the matching visits. For the HAART
naïve HIV positive women, we included all of their QOL
visits as candidate matching visits. The matching visit data
from the HAART exposed group and the candidate match-
ing visit data from the HAART naïve group were pooled
together and a propensity score was obtained for each par-
ticipant at each visit conditional on a number of variables,
including age, education, race/ethnicity, income, employ-
ment, health insurance, CD4+ cell counts, viral load, his-
tory of AIDS diagnosis, clinical depression, and number
Boxplots of QOL summary score between HAART users and HAART naïve groups before and after propensity-score match- ing Figure 1
Boxplots of QOL summary score between HAART users and HAART naïve groups before and after propensity-score match-
ing. Box widths are proportional to the number of observations in each group.
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Table 2: Estimates of the Impact of HAART on the Mean Change in QOL Scores from Propensity-Score Matched Pattern Mixture 
Models.
Model 1a Model 2b Model 3c Model 4d Model 5e
Effect P-Value Effect P-Value Effect P-Value Effect P-Value Effect P-Value
Summary QOL 
Score
Short-Term 
HAART Effect
2.07 0.11 2.25 0.07 2.26 0.07 2.24 0.08 3.25 0.02
Change per 6 
months
-0.30 0.01 -0.30 0.01 -0.21 0.08 -0.29 0.02 -0.29 0.01
Physical 
functioning
Short-Term 
HAART Effect
0.71 0.70 0.72 0.70 0.83 0.66 0.15 0.94 1.86 0.35
Change per 6 
months
-0.39 0.02 -0.39 0.02 -0.28 0.14 -0.36 0.07 -0.30 0.10
Role functioning Short-Term 
HAART Effect
5.08 0.01 5.40 0.01 5.46 0.01 5.98 0.01 6.99 0.00
Change per 6 
months
-0.40 0.04 -0.36 0.07 -0.34 0.11 -0.47 0.03 -0.45 0.04
Energy/fatigue Short-Term 
HAART Effect
-0.09 0.96 0.37 0.83 0.32 0.86 0.43 0.81 1.24 0.51
Change per 6 
months
-0.30 0.06 -0.31 0.05 -0.19 0.28 -0.21 0.24 -0.26 0.13
Social 
functioning
Short-Term 
HAART Effect
4.33 0.01 4.96 0.00 4.90 0.01 5.03 0.01 5.74 0.00
Change per 6 
months
-0.22 0.19 -0.19 0.25 -0.13 0.47 -0.19 0.30 -0.19 0.30
Cognitive 
functioning
Short-Term 
HAART Effect
2.58 0.08 3.51 0.02 3.46 0.02 3.48 0.03 3.59 0.03
Change per 6 
months
-0.08 0.57 -0.07 0.61 0.07 0.64 0.04 0.78 -0.04 0.82
Pain Short-Term 
HAART Effect
4.53 0.01 4.33 0.02 4.33 0.02 4.65 0.02 6.73 0.00
Change per 6 
months
-0.25 0.15 -0.26 0.14 -0.10 0.58 -0.21 0.29 -0.19 0.32
Emotional well-
being
Short-Term 
HAART Effect
2.38 0.12 2.46 0.12 2.47 0.12 2.45 0.12 2.05 0.20
Change per 6 
months
-0.16 0.25 -0.17 0.23 -0.18 0.23 -0.26 0.11 -0.30 0.05
Health 
perception
Short-Term 
HAART Effect
2.60 0.10 3.05 0.06 3.04 0.06 3.43 0.04 3.67 0.03
Change per 6 
months
-0.49 0.00 -0.49 0.00 -0.45 0.00 -0.50 0.00 -0.53 0.00
Perceived health 
index
Short-Term 
HAART Effect
4.25 0.00 4.79 0.00 4.67 0.00 4.65 0.00 4.87 0.00
Change per 6 
months
-0.08 0.86 -0.09 0.87 -0.11 0.87 -0.11 0.84 -0.09 0.83
a Model 1: Model includes an intercept, an indicator of HAART or HAART-naïve group (Short-Term HAART Effect) and the time from index visit 
(Change per 6 months).
b Model 2: Model 1 + age, ethnicity and education level.
c Model 3: Model 2 + income, employment and health insurance.
d Model 4: Model 3+ CD4+ cell counts and viral load.
e Model 5: Model 4+ number of symptoms, outpatient visits, hospitalizations and medication, AIDS history and clinical depression. Interactions 
between HAART and time from index visit were not statistically significant for all models.AIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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of symptoms, outpatient visits, hospitalizations and med-
ications, QOL scores and calendar time. Every HAART
user was matched to one randomly selected HAART naïve
participant at a baseline visit with an equivalent (within
0.1% rounding level) propensity score of HAART initia-
tion. For any HAART unexposed individual selected as a
control, the rest of her visits were removed to ensure 1:1
matching. To evaluate the effect of propensity score
matching, T tests and chi-square tests were performed to
test differences in the distributions of background varia-
bles between the exposed and unexposed groups before
and after matching.
Pattern mixture model analysis
After matching, the differences of the QOL summary score
and the nine domain scores at each visit from their values
at the matching baseline visit were used as the study out-
comes. To evaluate the effect of HAART, a conventional
random effects mixture model could be fit if data were
missing only at random, e.g. not related to study out-
comes. However, in our analysis, a substantial proportion
(33%) of participants, especially those from the HAART
naïve group (46%), died during the study follow-up. To
obtain a better estimate of changes over time, we utilized
a pattern mixture model approach where data were strati-
fied by the pattern of follow-up and distinct models were
constructed within each stratum[24] To implement this
approach, we grouped the drop-out times into 4 catego-
ries (≤ 2, 2.1–4, 4.1–6, and ≥ 6 years) and assumed that
the distribution of response would be a weighted mixture
over drop-out categories[25]. The overall estimates of var-
iable coefficients and standard errors were obtained across
the pattern.
In each model, we included an overall intercept term, a
binary indicator for HAART vs. HAART-naïve groups, and
a variable reflecting the time (in per 6 months) from the
baseline visit, which formed Model 1. Thus, the HAART
indicator reflects short-term effects of HAART and the
term for time reflects whether this change persists over fol-
low-up. To assess if HAART impacts the overall long-term
trend, we fit interaction terms between HAART and time.
Furthermore, in order to account for residual confound-
ing and explore possible mediators of how HAART exerted
its effect on QOL, a series of models were fit with different
combinations of covariates added to previous models:
Model 2 added baseline age, ethnicity, and education var-
iables to Model 1, Model 3 added time-varying socioeco-
nomic variables of income, employment, and health
insurance to Model 2, Model 4 added time-varying CD4+
cell counts and viral load to Model 3, and Model 5 added
time varying symptoms, outpatient visits, hospitaliza-
tions, medications, AIDS and depression to Model 4. All
statistical analyses were performed using a SAS version 9.1
(SAS Institute, Cary, NC) and Splus 7.0 (Insightful, Seat-
tle, WA).
Results
Table 1 displays the differences in the distributions of
baseline covariates between the HAART users and HAART-
naïve groups before and after matching. Prior to propen-
sity score matching, the distributions of risk factors affect-
ing HAART initiation were compared between 1,271
HAART exposed (the last visits before matching) and 555
HAART naïve participants (at candidate matching visits).
Thirteen out of the 24 background covariates, including
education level, race/ethnicity, income, insurance, CD4+
cell counts, viral load, AIDS diagnosis, number of symp-
toms, outpatient visits and medications, physical func-
tioning, perceived health index and health rating, were
significantly different between the groups, which necessi-
tated the matching of these covariates in our study. Using
a tolerance of 0.1% in the propensity score, we were able
to obtain 458 matched pairs of HAART initiators and
HAART naïve women. No statistically significant differ-
ences were observed for any of these background covari-
ates after matching (Table 1), which demonstrated a
success in matching the covariates as expected. The result-
ing distributions of propensity scores for the two groups
before and after matching are displayed in Figure 1. Before
matching, the average propensity scores for HAART using
and naïve groups were 0.42 and 0.22 respectively. How-
ever, after propensity score matching, the distributions of
propensity scores were nearly identical (mean: 0.36;
standard deviation: 0.17 for both groups).
The 916 matched participants had a mean age of 38.5
years at baseline and contributed a total of 4,292 person
visits, with a median follow-up time of 4 years (interquar-
tile range (IQR): 1–6 years). Among these women, about
58% were Black, non-Hispanics, 60% completed high
school and 42% had an AIDS history at the matching vis-
its. At baseline, the average CD4+ cell count was approxi-
mately 340 cells/mm3, the mean viral load was
approximately 10,000 copies/ml and the mean QOL sum-
mary score was 62. About 63% of HAART naïve women
dropped during the first two years, while the percentage
was only 11% for women using HAART. In contrast, only
11% of HAART naïve women were followed for 6 or more
years whereas the percentage for the women using HAART
was 38%.
To evaluate how HAART affected QOL change, we fit a
series of pattern mixture models with different subsets of
covariates (Table 2). In each model, HAART use and time
from matching visits were included. We first examined
whether there were any significant interactions between
time and HAART use to assess any long-term HAART effect
on QOL score changes. As the interaction terms were notAIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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Table 3: Estimates of the Impact of HAART on the Mean Change in QOL Scores from Propensity-Score Matched Pattern Mixture 
Models among AIDS-free Women at Matching Visits
Model 1a Model 2b Model 3c Model 4d Model 5e
Effect P-Value Effect P-Value Effect P-Value Effect P-Value Effect P-Value
Overall QOL Short-Term 
HAART Effect
0.57 0.70 0.40 0.79 0.43 0.78 0.63 0.69 1.61 0.35
Change per 6 
months
-0.24 0.10 -0.26 0.08 -0.19 0.23 -0.26 0.11 -0.20 0.16
Physical 
functioning
Short-Term 
HAART Effect
0.05 0.98 -0.19 0.94 -0.23 0.92 -0.88 0.73 0.55 0.83
Change per 6 
months
-0.27 0.25 -0.28 0.23 -0.26 0.31 -0.37 0.14 -0.25 0.26
Role functioning Short-Term 
HAART Effect
2.48 0.33 2.61 0.30 2.73 0.28 3.03 0.24 4.13 0.12
Change per 6 
months
-0.30 0.25 -0.26 0.32 -0.28 0.33 -0.33 0.26 -0.26 0.35
Energy/fatigue Short-Term 
HAART Effect
-2.22 0.30 -2.12 0.31 -2.14 0.31 -1.67 0.44 -0.71 0.75
Change per 6 
months
-0.25 0.22 -0.30 0.16 -0.19 0.42 -0.26 0.27 -0.24 0.28
Social 
functioning
Short-Term 
HAART Effect
3.17 0.12 3.71 0.08 3.85 0.08 4.33 0.05 5.27 0.02
Change per 6 
months
-0.17 0.43 -0.16 0.44 -0.08 0.73 -0.09 0.71 0.01 0.97
Cognitive 
functioning
Short-Term 
HAART Effect
0.86 0.61 2.21 0.22 2.23 0.22 2.54 0.16 2.38 0.22
Change per 6 
months
-0.13 0.46 -0.11 0.52 -0.05 0.79 -0.06 0.76 -0.11 0.54
Pain Short-Term 
HAART Effect
3.25 0.13 2.53 0.24 2.69 0.21 3.46 0.13 5.96 0.02
Change per 6 
months
-0.21 0.36 -0.26 0.28 -0.11 0.67 -0.17 0.52 -0.11 0.66
Emotional well-
being
Short-Term 
HAART Effect
1.56 0.40 1.06 0.58 1.06 0.58 1.02 0.58 0.17 0.93
Change per 6 
months
-0.19 0.32 -0.18 0.34 -0.16 0.42 -0.20 0.36 -0.23 0.26
Health 
perception
Short-Term 
HAART Effect
0.07 0.97 0.36 0.84 0.27 0.88 0.31 0.87 0.45 0.82
Change per 6 
months
-0.36 0.04 -0.37 0.04 -0.37 0.06 -0.50 0.01 -0.54 0.00
Perceived health 
index
Short-Term 
HAART Effect
3.17 0.07 3.76 0.03 3.46 0.05 4.03 0.02 4.08 0.03
Change per 6 
months
-0.21 0.21 -0.20 0.22 -0.28 0.11 -0.31 0.08 -0.26 0.14
a Model 1: Model includes an intercept, an indicator of HAART or HAART-naïve group (Short-Term HAART Effect) and the time from index visit 
(Change per 6 months).
b Model 2: Model 1 + age, ethnicity and education level.
c Model 3: Model 2 + income, employment and health insurance.
d Model 4: Model 3+ CD4+ cell counts and viral load.
e Model 5: Model 4+ number of symptoms, outpatient visits, hospitalizations and medication, AIDS history and clinical depression. Interactions 
between HAART and time from index visit were not statistically significant for all models.AIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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statistically significant in any model (though its direction
was positive), it was dropped out from our analyses. Then,
we evaluated the overall effect of HAART on changes of
QOL scores (the summary score and nine specific QOL
domain scores) without time varying intermediate varia-
bles (models 1–2) and the direct effects of HAART after
adjusting for different possible mediating covariates
(models 3–5).
Compared with the HAART naïve group in the bivariate
model (Model 1) with HAART use and time as the only
covariates, the HAART users had improved QOL scores
from the matching visits for almost all domains except for
energy/fatigue, with those for role functioning (mean
change: 5.08; P  = 0.01), social functioning (4.33; P  =
0.01), pain (4.53; P = 0.01) and perceived health index
(4.25; P < 0.01) reaching a statistically significant level. A
second model (Model 2) was fit by adding fixed personal
characteristics, including age at baseline, race/ethnicity
and education at study enrollment, into the bivariate
model. The model estimates for HAART and time changed
slightly except for cognitive functioning, which became
statistically significant (3.51; P = 0.02). In Model 3, we
included time-dependent socioeconomic variables –
income, employment and health insurance into the
Model 2. No significant change of HAART effect was
observed. After further adding markers for disease pro-
gression (CD4+ cell counts and HIV viral load) as in the
Model 4, the HAART effects remained stable except for
health perception (3.43; P  = 0.04). In the final model
(Model 5), the clinical variables (number of symptoms,
outpatient visits, hospitalizations and medications, his-
tory of AIDS diagnosis and clinical depression) were
added as covariates into the Model 4. Except for cognitive
functioning, health perception and perceived health
index, adding clinical variables into the models was asso-
ciated with biggest changes in HAART effect estimates. In
addition, the direct HAART effect on summary QOL
change became significant (3.25; P = 0.02). Furthermore,
though the QOL scores decreased over time for almost all
domains in all models, only the decreases of summary
QOL, role functioning, emotional well-being and health
perception were statistically significant in the final model
after controlling many time varying covariates.
As the HIV-infected individuals at different disease stages
might have different responses to HAART, we further
examined the association of HAART and QOL among
women who were AIDS-free at the matching visits (Table
3). Again, all QOL domain scores remained stable or
decreased (for health perception) during follow-up, and
HAART use did not modify these trends. Compared to the
Table 2, fewer QOL domains were significant for short-
term HAART effects (social function, pain and health rat-
ing) and it was negative for the energy/fatigue domain.
In addition to HAART use and time, a number of the cov-
ariates were significantly associated with QOL changes
from baseline. Evaluating the results from Model 5 for the
summary QOL change, women having less than high
school education had slightly higher summary QOL
change (3.12; P = 0.02) compared to women with college
education at study enrollment. In addition, all clinical
variables were significantly associated with summary
QOL change. Having one more symptom, outpatient visit,
hospitalization or medication was associated with a
decrease of 2.17 (P < 0.01), 0.11 (P < 0.02), 1.57 (P <
0.01) or 0.24 (P < 0.01) in summary QOL change respec-
tively. Depression was strongly related to a decline in
summary QOL change (-9.78; P < 0.01), while having a
history of clinical AIDS was associated with improved
QOL change (2.13; P = 0.04). All other demographic, soci-
oeconomic and biological (CD4+ cell counts and HIV
viral load) variables were not significantly associated with
QOL changes from baseline.
Discussion
In our study, we attempted to obtain unbiased estimates
of HAART effects on QOL in WIHS by minimizing indica-
tion bias and further adjusting for the effect of informative
drop-outs using several innovative statistical methods. By
balancing the distributions of observed background cov-
ariates using propensity score matching, the observational
studies come closer to mimicking the effect of rand-
omized clinical trials with equivalent probability of
receiving treatment. In addition, application of joint mod-
eling skills like pattern mixture model is one method to
handle the informative drop-outs which may bias effect
estimates in longitudinal studies.
Our study showed that HAART improved most QOL
domains relatively quickly. Most of these domains were
stable or showed slight declines over subsequent follow-
up, and there was no indication that HAART modified
these trends. These results suggest that continued use of
HAART did not result in continued improvement in QOL
domains. This lack of long-term effect might reflect a bal-
ance between reduced HIV-related symptoms and added
side effects from HAART. As many time-dependent varia-
bles were controlled already, the likely explanation for
QOL decrease over time might be due to aging or other
uncontrolled factors. It should be noted that the QOL
decrease trends were not entirely homogeneous. Examin-
ing results from different drop-out patterns revealed that
women with the shortest maximum follow-up time had
the highest rate of QOL decrease in both groups (data not
shown). As early drop-out due to causes like death is usu-
ally associated with faster disease progression and quicker
deterioration of QOL, appropriate handling of informa-
tive drop-outs using a pattern mixture model was justified
in our analysis.AIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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By adding different combinations of covariates step by
step into the models, we could explore the possible medi-
ators through which HAART renders its effect. In the bivar-
iate models, HAART use had positive overall effects for
almost all QOL domains, which is congruent with some
clinical trial results with relative short follow-up peri-
ods[10,11]. Because fixed demographic covariates were
already controlled at baseline by matching, it is not sur-
prised that adding these variables did not substantially
alter the estimated HAART effects. Addition of time vary-
ing socioeconomic variables did not change the estimates
much either, indicating that these covariates had been sta-
ble through the study follow-up. Though HAART could
decrease viral load dramatically and increase CD4+ cell
counts accordingly, the observed HAART effects did not
differ substantially with and without these variables in the
models. This phenomenon might be explained by the
weak associations between these biological variables and
QOL[1,26]. Finally, with the inclusion of the time varying
clinical variables, the estimates of HAART effect experi-
enced the biggest improvement for most QOL domains,
providing evidence that these clinical covariates served as
mediate factors and had negative impacts on QOL. In
addition, the significance of direct HAART effects on most
QOL domain scores implies that HAART might have ren-
dered its effect through pathways other than improving
the patient's immune status or changing clinical profile.
One of the multiple possible explanations for this may be
simply a placebo effect resulting from relieved stress for
the infected individuals[27] using HAART because the
effectiveness of HAART in reducing AIDS-related morbid-
ity and mortality has been demonstrated. Similar to previ-
ous studies[6,7], HAART had different effects for
individuals at different disease stages, with short-term
improvements of all QOL domains for AIDS patients and
deterioration of certain QOL domain for AIDS-free HIV-
infected individuals. Thus, it would be advisable to think
about the timing of initiating HAART, especially for those
individuals at their early stage of HIV disease, to maximize
their quality of life.
The propensity score method has been widely applied in
observational studies through matching, stratification, or
weighting to obtain estimates that may be less biased,
more robust and precise[28]. By generating a propensity
score from many risk factors affecting HAART initiation,
the overall effect of these factors on starting HAART can be
represented by this scalar summary score. Through match-
ing with the propensity score, the associations between
these risk factors and HAART initiation are blocked and
these covariates no longer act as confounders. Noticeably,
the distributions of all covariates that were substantially
different before matching became identical after match-
ing, which convincingly showed that the matching did
what we expected. Furthermore, the HAART effect esti-
mates were relatively stable across models with different
combinations of covariates, indicating indirectly that the
matching successfully turned many covariates into non-
confounders. However, two possible limitations should
also be noted. First, we could not find a sufficiently close
match for all individuals. In our dataset, the HAART naïve
group was smaller (N = 555) than the HAART initiators (N
= 1271). In order to have a 1:1 match, we had to restrict to
the smaller group, and could only find a match for 83%
of these individuals. This is common in propensity score
analyses. Second, although the propensity score adjusting
method is very effective in balancing the known con-
founders across groups, omission of important unob-
served confounders might still lead to residual
confounding in estimating treatment effect. In our study,
we included many possible confounders identified from
prior studies in estimating the propensity score and exam-
ination of other potential variables such as substance
abuse and violence history did not show any difference.
Thus, the chance of leaving out important confounders
was minimized. Of course, omission of unmeasured con-
founders is a constant threat to the validity of non-inter-
ventional studies as well.
In our intent-to-treat analysis, we assumed that individu-
als who started HAART would remain on HAART through-
out the follow-up. Though some participants may have
discontinued HAART for a few visits, our data showed that
the HAART users had been on HAART for about 80% of
their follow-up visits. We did not take into account the
adherence to HAART in our analysis though we have con-
trolled some variables, including age and viral load, that
contribute to the lower level of adherence to HAART
use[29]. In our analysis, we examined the effects of
HAART as a whole, rather than the effects of specific
HAART regimens on QOL. As HAART regimens vary from
individual to individual and from time to time within the
same individual in WIHS, it is nearly impossible to assess
the effect of every regimen on QOL change given the
numerous number of HAART regimens used. In addition,
we did not analyze the effect of HAART-related side effects
on QOL due to insufficient data. However, as we control-
led for clinical variables which are related to both HAART
effectiveness and HAART-related side effects, the heteroge-
neity of HAART regimen effects could be predicted and
effect of drug side effects could be partially controlled. In
addition, our study subjects are comprised of women at a
relatively advanced stages of disease, thus the observed
HAART effects may not be representative of the general
HIV-infected population.
In WIHS, a shortened version of MOS-HIV form was used
to assess QOL change among the participants. The relia-
bility and construct validity of this instrument have been
demonstrated and the burden for both investigators andAIDS Research and Therapy 2006, 3:6 http://www.aidsrestherapy.com/content/3/1/6
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patients was alleviated due to reduced administration
time [19]. Though MOS-HIV form has been frequently
used in HIV research since the last decade[30], it has rela-
tively limited application among women, minorities and
individuals with lower socioeconomic status[31]. As the
largest HIV/AIDS prospective cohort of women in the US,
the WIHS represents an ethnically diverse, socioeconomi-
cally disadvantaged group with complex risk factors
whose QOL status has not been well studied. Thus, our
analysis will provide important initial information of
QOL change for women in the HAART era.
In summary, we evaluated the effects of HAART on QOL
among women in the WIHS. HAART did not show any
long-term effect on QOL changes, but had short-term
direct effects not mediated through clinical variables.
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